310 related articles for article (PubMed ID: 3343727)
1. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR
J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.
Scher HI; Yagoda A; Herr HW; Sternberg CN; Bosl G; Morse MJ; Sogani PC; Watson RC; Dershaw DD; Reuter V
J Urol; 1988 Mar; 139(3):470-4. PubMed ID: 3343728
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors.
Scher HI; Yagoda A; Herr HW; Sternberg CN; Morse MJ; Sogani PC; Watson RC; Reuter V; Whitmore WF; Fair WR
J Urol; 1988 Mar; 139(3):475-7. PubMed ID: 3343729
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer.
Ueki O; Hisazumi H; Uchibayashi T; Naito K; Tajiri S; Takemae K; Kawaguchi K; Kameda K; Nishino A; Nango C
Cancer Chemother Pharmacol; 1992; 30 Suppl():S72-6. PubMed ID: 1394823
[TBL] [Abstract][Full Text] [Related]
7. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
Igawa M; Kadena H; Ohkuchi T; Ueda M; Usui T
Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
Pizzocaro G; Milani A; Piva L; Faustini M; Spino E
Eur Urol; 1991; 20(2):89-92. PubMed ID: 1752280
[TBL] [Abstract][Full Text] [Related]
9. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.
Ogawa T; Gotoh A; Takenaka A; Hara I; Gohji K; Arakawa S; Matsumoto O; Kamidono S
Cancer Chemother Pharmacol; 1992; 30 Suppl():S66-71. PubMed ID: 1394822
[TBL] [Abstract][Full Text] [Related]
11. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of urothelial tract tumors.
Yagoda A
Cancer; 1987 Aug; 60(3 Suppl):574-85. PubMed ID: 3297286
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract--a preliminary report.
Lee MH; Chen MT; Chen KK; Lin AT; Lee YH; Lee LM; Chang YM; Chang LS; Liu JM; Hsieh RK
Cancer Chemother Pharmacol; 1992; 30 Suppl():S81-4. PubMed ID: 1394825
[TBL] [Abstract][Full Text] [Related]
16. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
Kobayashi H; Obata K
Cancer Chemother Pharmacol; 1994; 35 Suppl():S14-7. PubMed ID: 7994781
[TBL] [Abstract][Full Text] [Related]
17. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium.
Miller RS; Freiha FS; Reese JH; Ozen H; Torti FM
J Urol; 1993 Jul; 150(1):65-9. PubMed ID: 8510277
[TBL] [Abstract][Full Text] [Related]
19. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
